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Abstract
Cell lines represent the everyday workhorses for in vitro research on multiple myeloma (MM) and are regularly employed in
all aspects of molecular and pharmacological investigations. Although loss-of-function studies using RNA interference in
MM cell lines depend on successful knockdown, no well-established and widely applied protocol for efficient transient
transfection has so far emerged. Here, we provide an appraisal of electroporation as a means to introduce either short-
hairpin RNA expression vectors or synthesised siRNAs into MM cells. We found that electroporation using siRNAs was much
more efficient than previously anticipated on the basis of transfection efficiencies deduced from EGFP-expression off
protein expression vectors. Such knowledge can even confidently be exploited in ‘‘hard-to-transfect’’ MM cell lines to
generate large numbers of transient knockdown phenotype MM cells. In addition, special attention was given to developing
a protocol that provides easy implementation, good reproducibility and manageable experimental costs.
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Introduction
Multiple myeloma (MM) is a cancer affecting terminally
differentiated plasma B cells [1]. MM accounts for about 15%
of newly diagnosed hematologic cancers [2,3] and the recent
development of novel treatment options has led to considerably
longer median survival [4]. While prolonged patient survival is
being reported after the application of novel therapy regimens
[5,6], MM is generally still considered incurable with particularly
unfavourable prognoses for certain genetically-defined patient
subgroups [7,8].
The profound advances in sequencing technologies now permit
the use of primary MM cells to characterise an ever larger range of
genetic traits throughout the course of a patient’s disease [9,10,11].
Nevertheless, human MM cell lines (HMCLs) are and will remain
indispensable as tools for functional in vitro analyses and
preclinical development of novel treatment approaches. Growing
in suspension and/or semi-adherently, HMCLs do not count as
particularly amenable to transient transfection with nucleic acids.
Few publications have specifically addressed this topic [12,13] and
although a roster of anecdotal evidence implies various transient
transfection methodologies for use with (specific) HMCLs
[14,15,16,17,18,19,20], no broadly-used method of choice has so
far emerged – not least, because transfection efficiency is usually
either perceived as low or not easily determined in the first place.
RNAi knockdown experiments in HMCLs can usefully comple-
ment pharmacologic inhibition studies and also offer a chance to
target undruggable proteins. We have over the past ten years
successfully used transient transfection of HMCLs with pSUPER
short hairpin RNA expression vectors via electroporation
[21,22,23,24,25]. To overcome the disadvantage of low transfec-
tion efficiencies we have applied a specific purification step, which
leads to very pure fractions of strongly transfected cells [21,23].
However, the necessity for purification adds to the amount of
work-time needed, potentially increases the stressfulness of the
whole methodology and also increases the overall cost of the
procedure. Although this method can in principle be scaled up at
will, it is in practice rather cumbersome to isolate high numbers
(i.e. ‘‘millions’’) of strongly transfected MM cells. We therefore
tested the efficiency of knockdown approaches using the same
electroporation conditions but employing siRNA or stealth siRNA
oligonucleotides instead of short-hairpin expression vectors.
This manuscript describes in detail the procedures for plasmid
versus oligonucleotide electroporation into HMCLs, compares the
respective transfection and knockdown efficiencies and discusses
the advantages and disadvantages of both experimental settings.
Our aim is to summarise our experience with electroporation of
MM cell lines that work well in our hands and to provide efficient
models for functional analyses. We therefore explicitly intend to
convey our personal take on all practical aspects connected to
these tasks in order to provide solid guidance on how to plan,
perform and interpret such experiments. Other points considered
are the potential for easy application of these protocols in other
laboratories, good feasibility of the procedures in the hands of
researchers and technicians, and strict cost effectivity in order to
serve as a workable standard procedure.
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Materials and Methods
Human Multiple Myeloma Cell Lines (HMCLs)
HMCLs (AMO-1, JJN-3, L-363, OPM-2, RPMI-8228) were
bought at the German Collection of Microorganisms and Cell
Cultures (DSMZ; Braunschweig, Germany). INA-6 cells were a
gift from Martin Gramatzki (University Medical Center Schleswig-
Holstein, Kiel, Germany) [26]. After acquisition the cells were
immediately expanded to create a stock bank of 50 vials stored in
liquid nitrogen. One of these vials was then used to generate a
working bank of between 30–50 vials. Every 3–4 months current
cell cultures were retired and reinstated from the respective
working banks (dead-end culture). Stock and working banks were
confirmed to be negative for mycoplasma [27] at the time of their
creation, and current cell cultures were also regularly tested. All
cells were cultured at 5% CO2, 37uC, in RPMI-1640 medium
supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM
glutamine, and 100 U/ml penicillin +100 mg/ml streptomycin.
INA-6 cells were supplied with 2 ng/ml recombinant human
interleukin-6.
Reagents
Annexin V was prepared according to the protocol detailed in
[28], coupled to PromoFluor 647 using its commercially available
N-hydroxysuccinimidyl ester (PromoCell, Heidelberg, Germany;
PK-PF647-1), and the final concentration adjusted such that 1 ml
produced a maximal signal shift in FACS measuremants of MM
cells. Stealth siRNA against enhanced green fluorescent protein
(cat. no. 12935-145) and custom-built stealth siRNA against
human ERK2 (59-GAGGAUUGAAGUAGAACAGGCUCUG-
39, equivalent to bases 900 to 924 of human ERK2) were obtained
from Life Technologies (Darmstadt, Germany). 6-carboxyfluor-
escein (6-FAM)-labelled siRNA against ERK2 (59-fluorescein-
AAGAGGAUUGAAGUAGAACAG-dTdT-39, a shorter version
of the sequence mentioned above) was from Qiagen (Hilden,
Germany). The pcDNA3.1-CD4D and the pSUPER-ERK2
vectors are described in [21].
Electroporation of MM Cells
MM cells from routine cultures (cell densities 36105276105/
ml) were pelleted at 3006g and resuspended in fresh RPMI-1640
medium (i.e. freshly opened medium or medium stored at such
conditions that preserve the pH of the unopened bottle [e.g. 15 ml
screwcap tubes filled to the brim]) without additives. Cell densities
in the final electroporation mix varied from between 26107/ml to
66107/ml, which for electroporations in 2 mm cuvettes (200 ml
volume) represents a range from 0.4610721.26107 cells per
electroporation, and for 4 mm cuvettes (500 ml volume) translates
to 16107236107 cells per shot. Plasmid and/or siRNA solutions
were dispensed into 1.5 ml Eppendorf tubes and mixed with the
cell suspension by gentle pipetting. The complete range of
electroporation mixes was prepared and electroporation carried
out with a Gene Pulser (Bio-Rad Laboratories, Mu¨nchen,
Germany) at a capacity setting of 960 mF and with voltages
ranging from 150 V-350 V. A single exponential decay pulse was
applied and cell suspensions were immediately removed from the
cuvette and pipetted into another tube containing 500 ml fresh
medium without additives. Samples were left standing at room
temperature until all electroporations were finished. Cells were
then transferred to dishes with prewarmed full medium for further
culture at standard conditions.
Tip: Re-use of electroporation cuvettes is permissible, at least
when no use of electroporated cell material for PCR purposes is
intended. We routinely use one cuvette for sequential performance
of all electroporations within one experimental series, thoroughly
rinsing it with PBS (squirt bottle) and quickly draining the cuvette
(hitting it onto paper towels) in between electroporations.
Afterwards the cuvette is cleaned with PBS and with EtOH and
air-dried. This procedure can be repeated several times without
significant loss of electroporation efficiency. Monitoring transfec-
tion efficiency by adding some pEGFP-N3 vector will help to
establish a sensible routine.
Note: The use of really ‘‘fresh’’ medium in the cell suspension
intended for electroporation was the most (in fact the only) critical
factor for cell survival (at 280 V, a voltage that permitted the best
transfection efficiency as measured by EGFP expression from
pEGFP-N3) when we established this protocol for INA-6 cells (in
contrast to such parameters as temperature before or after
electroporation, recovery times, DNase-treatment after electropo-
ration, cell density in culture or in the electroporation mix,
presence of phenol red). This may reflect a particular sensitivity of
INA-6 cells to the pH conditions of the solution after electropo-
ration, and it need not necessarily be the same for other HMCLs.
Because it is not much extra work we have simply extended this
procedure to all HMCLs without further specific elaboration.
Purification of Electroporated MM Cells
For simple removal of debris and dead cells the cell cultures at
either day 1 or day 2 post-electroporation were pelleted and
resuspended in a mixture of OptiPrep (a 60% solution of
iodixanol; Progen Biotechnik, Heidelberg, Germany) with full
medium (2.5 ml medium + 0.75 ml OptiPrep). The cell suspen-
sions were overlayered with 200 ml PBS and centrifuged for 5 min
at 4,0006g. Live cells, assembled at the interface between
OptiPrep/medium and PBS, were once washed with full medium
and taken into culture for further use in experiments.
For the column purification procedure using MACSelect 4
MicroBeads (Miltenyi Biotech, Bergisch-Gladbach, Germany) the
cell cultures at either day 1 or day 2 post-electroporation were first
washed with PBS and then with cold column buffer (PBS with
0.5% FBS and 2.5 mM EDTA). After resuspension in 340 ml cold
column buffer 60 ml CD4 MicroBeads (Miltenyi Biotech, cat. no.
130-070-101) were added, and the mixture was incubated for 10–
20 min at 4uC with occasional flicking. Samples were run over
paramagnetic bead-filled columns (Large cell columns, Miltenyi
Biotech, cat. no. 130-042-202), these were washed with cold
column buffer, removed from the magnet and the retained cells
flushed out with 2 ml full medium. Because the column run also
retains significant numbers of dead cells it is necessary to
subsequently subject the eluate to the above-described OptiPrep
purification procedure.
Note: It is not useful to perform dead cell removal before the
column run, because the column procedure will re-concentrate the
small amount of debris that is still present and the end result is
much dirtier.
Tip: The paramagnetic bead columns can be re-used. For
regeneration we flush them 3–4 times with hot tap water, then
once with distilled water (to remove salts) and finally with 96%
ethanol (to remove most of the water). Columns are then quickly
dried in an incubator at up to 65uC (reasonably quick drying is
necessary because otherwise the columns turn rusty and should be
discarded). To re-use these columns, 100 ml 80% ethanol is
applied in order to ensure good wetting of the beads and complete
air removal from the column before the new sample is loaded.
Tip: In order to restrict the flow rate through the Large cell
columns the company provides flow resistors (i.e. 23 gauge
hypodermic needles) with each box of columns. In our experience
and for reasons entirely unclear the use of 23 gauge needles from
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Terumo (Neolus, NN-2332R) results in considerably more
consistent sample flow and less occasions of complete flow
blockage.
Western Blotting and Antibodies
Frozen cell pellets were dissolved in Laemmlie-buffer (60 mM
Tris-HCl, 10% glycerol, 2% SDS, 10% b-mercaptoethanol,
0.01% bromophenol blue; pH 6.8) (10 ml buffer per 100,000 cells)
and subjected to sonication (3–5 s on ice with a UP50H sonicator
equipped with an MS1 sonotrode) (Hielscher, Teltow, Germany).
Samples were then heated to 89uC for 3 min, spun for 5 min at
room temperature and the supernatants used for standard SDS-
PAGE with 12% gels. Wet blotting was carried out in Mini Trans-
Blot modules (Bio-Rad Laboratories) using nitrocellulose mem-
branes and blotting buffer (20% v/v methanol, 25 mM Tris-HCl,
192 mM glycine, pH 8.6). The following antibodies were used for
target detection: anti-ERK1/2 (Cell Signaling Technology,
Frankfurt am Main, Germany; no. 9102), anti-ERK1/2 (Santa
Cruz Biotechnology, Heidelberg, Germany; sc-94), anti-phospho-
ERK1/2 (Cell Signaling Technology; no. 9101), anti-tubulin
(Biozol, Eching, Germany; BZL03568). The secondary antibodies
were from Jackson ImmunoResearch Laboratories (Newmarket,
UK): anti-rat-HRP (112-036-062), anti-rabbit HRP (111-036-045).
A freshly made solution of luminol (2.5 mM), p-coumaric acid
(0.2 mM) and H2O2 (0.01%) in 100 mM Tris-HCl (pH 8.8) was
used for chemiluminescent detection [29].
Flow Cytometry
Cells were washed with PBS, pelleted and resuspended in
200 ml of cold annexin V binding buffer (10 mM HEPES/NaOH,
140 mM NaCl, 2.5 mM CaCl2; pH 7.4) containing 1 ml of
annexin V-PromoFluor 647 solution (see Reagents) and 1 mg/ml
propidium iodide. Flow cytometry was performed using a
FACSCalibur (BD Biosciences, Heidelberg, Germany). Datafiles
were analysed with FlowJo version 8.8.7 (Tree Star, Inc., Ashland,
U.S.A.).
Statistical Analysis
Calculation of the ‘‘range overlap’’ in FACS-based measure-
ments for a given time-point: Measured events were gated for the
live cell population according to the forward/sideward scatter
pattern. The signal range containing the central 98% of events for
the control sample measurement (i.e. all events between the first
and the 99th percentile) was then determined. Finally, it was
calculated what percentage of the total events measured for the
targeted sample fell into this range.
Results and Discussion
Electroporation of HMCLs with Expression Plasmids
Followed by Cell Separation Yields Pure Fractions of
Strongly Transfected Cells
In order to obtain homogeneous fractions of transiently
transfected MM cells we have established a protocol that combines
electroporation with subsequent isolation of the most strongly
affected cells (Fig. 1). This methodology allows very good
knockdown efficiencies with pSUPER-based short-hairpin RNA
expression vectors (applied, for example, in [21,23,24,25]).
Transfection efficiency is judged by introduction of an expression
plasmid for EGFP (Fig. 1a), and – dependent on the HMCL –
transfection efficiencies of up to 40% can be achieved with
standard gear electroporations (Table 1). However, the large
fraction of EGFP-negative cells represents an undesired back-
ground which we have sought to eliminate. Either cell sorting for
EGFP-positive cells (not shown), or co-electroporation of an
expression plasmid for CD4D [21] and subsequent microbead
selection of CD4-positive cells (exemplarily shown in Fig. 1b–e)
can be employed to obtain highly enriched fractions of strongly
transfected cells (Fig. 1d, see Methods section for an exact
description of the purification steps). These cells can then be used
in experiments involving their actual payloads, for example co-
transfected shRNA expression vectors [21,23,24,25], and they are
suitable for transient knockdown studies in applications such as
apoptosis induction, drug testing, proliferation assessments or
Western blotting. Furthermore, the transfection procedure itself is
very cheap and permits easy scaling-up, because once effective
shRNA-expression plasmids have been generated they can be
produced at will and at very low cost. On the downside, FACS-
based cell isolation necessitates access to such a service, potentially
incurring fees and compelling researchers to abide by the
operator’s schedule. The microbead purification approach has
the advantage that it is fast and that all steps can easily be
performed in the laboratory. However, this protocol relies on an
expensive reagent (CD4 microbeads), and because the microbead
columns also retain dead MM cells (Fig. 1c) a density gradient
centrifugation step that removes this debris is required (Fig. 1d).
Last, not every HMCL seems able to implement extracellular
presentation of CD4D (most notably cell line AMO-1; TStu¨,
personal observation), rendering such cell lines unsuitable for
microbead purification protocols.
Electroporation of HMCLs with siRNA Oligonucleotides
Results in Homogeneous Transfection of the Whole
Viable Cell Population
Using commercial siRNA oligonucleotides instead of shRNA
expression plasmids in electroporations is considerably more
expensive. However, a much larger number of functional
siRNA-oligonucleotide sequences have been published, and
siRNA-oligonucleotide pools provide the fastest way to assess
molecular and biological effects of target knockdown when only
trial experiments or a limited set of electroporations are required.
We therefore decided to rigorously test if our protocol could be
adapted to perform (cost-) effective siRNA oligonucleotide-
mediated knockdown studies in MM cells. The central question
was whether the essentially EGFP-negative cell fraction (for
example, the 55.1% of cells logged in the lower left quadrant in the
JJN-3 electroporation shown in Fig. 1f) might nevertheless be
accessible to the much smaller RNA oligonucleotides, and whether
any such effects are strong enough to result in substantial and
reliable target depletion.
We first employed an siRNA against human extracellular signal-
regulated kinase 2 (ERK2) coupled to the fluorescent dye 6-
carboxyfluorescein (6-FAM) to monitor transfection and knock-
down efficiency in MM cell lines AMO-1 and RPMI-8226 (Fig. 2
and Fig. S1). ERK2 was chosen as a target because specific protein
depletion in relation to its homolog, ERK1, is readily detectable by
Western blotting with a single antibody, and because single ERK
isoform knockdown has no adverse effect on the survival or
proliferation of MM cells (TSts, personal observations). The
siRNA sequence was based on the same sequence that had been
found effective when used within an shRNA-expression vector
[21]. Shortly after electroporation with siERK2-6-FAM the whole
viable MM cell population showed a strong shift in fluorescence
(for example: a 43-fold shift of the median in the exemplary
experiment shown for AMO-1 cells in Fig. 2; a 25-fold shift of the
median in the exemplary experiment shown for RPMI-8226 in
Fig. S1), which within 24 h quickly declined to lower, although still
Multiple Myeloma Cell Electroporation
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clearly and universally detectable, levels. This was followed by a
slower decline in fluorescence intensity, until at days 6–7 the signal
was no longer detectable (Fig. 2). The range overlap (see Statistical
analysis) for 6-FAM-labelled siRNA transfected cells with control
siRNA transfected cells was just 1.3%60.35% (n = 3) for AMO-1
cells at the 0 h timepoint, indicating that initially virtually the
whole cell population had acquired the labelled siRNA. Although
Western blotting of cells harvested at days 3, 5 and 7 post-
electroporation confirmed reduced ERK2 levels at early time-
points in the siERK2-6-FAM treated fraction (Fig. 2; Fig. S1),
significant quantities of the protein still remained. These
experiments were therefore inconclusive: the universal shift in
fluorescence and its subsequent fast decline could represent a
genuine effect showing efficient introduction of the labelled siRNA
into MM cells with subsequent fast processing in the RNA-induced
silencing complex. However, the mediocre knockdown efficiency
would then have to be explained by poor siRNA performance,
possibly due to the presence of the fluorescent label. Alternatively,
if the initial strong shift in fluorescence intensity was mainly
artefactual, caused, for example, by labelled siRNA sticking to the
cell surface after electroporation, then the moderate ERK2
knockdown might have been the result of inefficient or random
introduction of the siRNA into the MM cell population.
We addressed these problems using a ‘‘reverse’’ approach. MM
cell line INA-6 was chosen for selection of clones with stable and
bright expression of EGFP, which were then electroporated with a
stealth siRNA against EGFP in order to characterise the decline of
green fluorescence (Fig. 3). Additionally, an expression plasmid for
CD4D was also added to the electroporation mixture, and half of
the transfected culture was subsequently purified by the CD4
microbead column procedure (i.e. yielding a relatively small
number of strongly transfected cells) whereas the other half was
only subjected to debris removal via OptiPrep gradient (i.e.
yielding viable cells without any selection for ‘‘strong transfec-
tion’’). FACS analysis of these cells showed that essentially the
whole culture underwent a strong decline in EGFP intensity,
which reached its nadir of less than 10% compared to mock-
transfected control cells at about 4 days post-electroporation
(Fig. 3). Notably, the extent of EGFP knockdown as well as its
duration were virtually identical between both purification
procedures, indicating that the siRNA had effectively and
indiscriminately been introduced into the large majority of cells
(Fig. 3). Conversely, electroporation of INA-6 cells with the EGFP-
N3 plasmid usually results in no more than 30% efficiency
(Table 1). The EGFP-range overlap between the siRNA-treated
and the mock transfected cells at day three post-electroporation
was 4.5%62.8% (n = 3) and these events always formed a neat
small peak right beneath the signal for the unaffected control cells
(Fig. 3). The true nature of this ‘‘untransfected background’’
remains unclear, however. Although somewhat lower, this peak
was also clearly visible in column-purified cell samples (Fig. 3), and
we consider it very unlikely that any cells would have been
Figure 1. Electroporation of MM cell lines and subsequent
purification of transfected cells. Shown is a representative example
of the procedure using the well-transfectable MM cell line JJN-3. This
standard column purification has now been performed hundreds of
times in our laboratory and is also easily applicable for MM cell lines
INA-6, KMS-11, L-363, MM.1S and U-266 (Table 1). a) Cell culture one day
after electroporation with expression plasmids for enhanced green
fluorescent protein (EGFP) and CD4D, showing about a quarter of cells
strongly positive for EGFP. b)-e) Enrichment of strongly transfected cells
by selection for CD4 surface expression (CD4 MicroBead column
selection). b) Column runthrough of cell culture shown in a). Of note is
the similar look with a), but with depletion of the strongest transfected
cells in b). c) Column eluate of the cell culture shown in a).
Untransfected cells (EGFP- and CD4D-negative) have effectively been
removed, but the column procedure tends to retain significant amounts
of dead cells (EGFP-negative, PI-positive). d) Floating fraction of the
column eluate as shown in c) after ‘‘density gradient’’ (more properly:
density step) treatment using OptiPrep, consisting mostly of viable and
strongly transfected cells. e) Pelleted fraction of the column eluate as
shown in c) after ‘‘density gradient’’ treatment using OptiPrep,
consisting mostly of debris. f) Removal of debris by OptiPrep treatment
from the cell culture as shown in a) without prior column separation,
leaving two main fractions which are either EGFP-negative, or distinctly
EGFP-positive. See Methods section for further details.
doi:10.1371/journal.pone.0097443.g001
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transfected with the CD4D expression plasmid but not with the
siRNA. These events might therefore rather represent dysfunc-
tional cells or cell remnants which were not damaged badly
enough to be excluded through forward/sideward scatter-based
gating (and the preceding debris removal via OptiPrep), but
without the structural integrity to perform siRNA-mediated
degradation of EGFP. Taken together, these experiments clearly
demonstrated that the electroporation of siRNAs into HMCLs can
be nearly 100% effective at conditions when only a fraction of the
cells are successfully transfected by expression plasmids (to be
precise: by the EGFP and CD4D protein expression plasmids).
This result potentially permits transient knockdown experiments in
HMCLs on a considerably larger scale, so that more and/or
different experiments (such as nuclear preparations) can be
performed. For example, a typical electroporation using 36107
JJN-3 cells might yield a final tally of about 16106 cells via the
column purification procedure, but should yield about 1.56107
cells if only debris removal is required. We therefore aimed to
characterise this methodology in further detail.
Short Hairpin RNA- versus Stealth siRNA-mediated ERK2
Knockdown in HMCLs
We electroporated different HMCLs (AMO-1, JJN-3, L-363)
using either a pSUPER-based shRNA expression plasmid against
ERK2 (pSU-ERK2; [21]) or a 25 bp stealth siRNA (stERK2,
based on the same core sequence as the shRNA, see Methods).
pSUPER empty vector-transfected cells served as respective
controls. At day 1 post-electroporation one half of each sample
was subjected to the CD4 microbead column purification
procedure (or to EGFP-based cell sorting for AMO-1 cells) and
the other half simply to debris removal via OptiPrep density
gradient. Cells were harvested for Western blotting and ERK1/2
staining up to day 5 post-electroporation (Fig. 4). Column
purification or cell sorting yielded excellent knockdown results
regardless of whether the shRNA expression plasmid or the stealth
siRNA were used (Fig. 4). Conversely, differences between these
reagents appeared if the cells were simply taken through the
OptiPrep density gradient routine. Knockdown efficiencies for the
stERK2 siRNA equalled those of the more complex purification
procedures, but higher levels of ERK2 (or of its intrinsically
activated form, phospho-ERK2) were observed for pSU-ERK2
transfections (Fig. 4). These experiments confirmed that electro-
poration using siRNA oligonucleotides represents a powerful and
easy way to target the whole HMCL population. Somewhat
surprisingly, the pSU-ERK2-mediated ERK2 knockdown in MM
cells purified just via OptiPrep gradient was often still quite
pronounced and certainly better than the presence of EGFP-
negative cells (usually upwards of 50%) would have suggested. This
effect was especially pronounced in AMO-1 cells, but was also
noticeable in JJN-3 (Fig. 4), suggesting that in terms of
electroporation efficiency the pSUPER plasmid (a 3.1 kb large
derivative of the cloning vector pBluescript) might often rank
closer to the much smaller siRNAs than to the EGFP protein
expression vector (4.7 kb).
Voltage Dependence of siRNA Electroporation in AMO-1
Cells
In practice (i.e. for a defined and fixed set of electroporation
parameters, such as electrode distance, volume, capacity, expo-
nential decay-type pulse), voltage is perhaps the most important
factor for transfection efficiency in electroporation [30]. Optimal
conditions for any specific cell line are a trade-off between the
number and signal intensity of affected cells on the one hand, and
the ratio of living to dead cells on the other. Based on EGFP-
expression from the pEGFP-N3 vector we found conditions of
270–310 V (at 960 mF with 4 mm cuvettes) most suitable to
achieve acceptable rates of transfection and survival for those MM
cell lines that are at all amenable to any such treatment (see
Table 1). However, given that the use of siRNAs in such
conditions resulted in virtually 100% transfection of the surviving
cells, we tested if siRNA-mediated knockdown efficiency was also
maintained at lower voltages, i.e. in conditions that exert lower
Table 1. Parameters for MM cell line electroporation.
HMCL
Optimal voltage range
with 4 mm cuvette,
max. 56107 cells/ml
Optimal voltage range
with 2 mm cuvette,
max. 2.56107 cells/ml Range of transfected cells using pEGFP-N3
AMO-1 270–300 V 170–180 V 20–30%
INA-6 270–280 V 170–180 V 20–30%
JJN-3 270–300 V 170–180 V 20–30%
KMS-11 270–300 V 180–200 V 20–30%
KMS-12-BM 270–300 V 180–200 V 20–30%
L-363 270–300 V 170–180 V 20–30%
MM.1S 300–320 V 180–200 V 20–30%
MOLP-8 260–270 V none 10–20%
NCI-H929 240–250 V none ,10%
OPM-2 240–250 V 170–200 V ,10%
RPMI-8226 270–300 V 160–180 V ,10%
U-266 270–300 V 220–240 V 10–20%
Rule-of-thumb voltage settings for different HMCLs as deduced from electroporation with an expression plasmid for enhanced green fluorescent protein (pEGFP-N3). All
transfections were carried out with a Gene Pulser (Bio-Rad) with a capacity setting of 960 mF. The whole unpurified cell culture was measured (FACS) at day one post-
electroporation. The percentage ranges given are to be considered as guidelines for standard results based on between 10 (cell lines not regularly used in our
experiments) and hundreds of electroporations (the regularly used ‘‘well-transfectable’’ MM lines). The best electroporations achieved have yielded up to 40% EGFP-
positive cells, but suboptimal conditions - for example due to overly high cell densities in the preceding cell culture - may result in lower efficiencies than indicated.
doi:10.1371/journal.pone.0097443.t001
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experimental stress. AMO-1 cells were electroporated across a
range of voltages with a mixture of the pEGFP-N3 vector (to
determine transfection efficiency by EGFP expression) and the
stERK2 siRNA (to determine transfection efficiency by ERK2
Figure 2. Electroporation of AMO-1 cells with a 6-FAM-labelled
siRNA oligonucleotide. Left column: Fluorescence of AMO-1 cells
electroporated with the siERK2-6-FAM oligonucleotide (green curve) in
relation to mock transfected cells (blue curve) at different time points
post-electroporation. Right: Western analysis for ERK2 knockdown at
days 3, 5, 7 post-electroporation. One representative experiment from a
total of three is shown. Anti-ERK1/2 antibody: CST.
doi:10.1371/journal.pone.0097443.g002
Figure 3. Electroporation of INA-6 cells stably expressing
enhanced green fluorescent protein with an siRNA oligonucle-
otide against EGFP. INA-6-EGFP cells were electroporated with a
solution containing a stealth siRNA targeting EGFP as well as an
expression plasmid for CD4D. One day post-electroporation one half of
the cell culture was purified according to the column procedure (red
curves, also see Fig. 1b)–e)), whereas the other half only underwent
debris removal with OptiPrep (blue curves, also see Fig. 1f)). Purified
cells were further cultured and FACS-analysed for EGFP expression at
the times indicated. Only the live cell fraction (as demarcated in the
forward/sideward scatter) was analysed and plotted against similarly
treated INA-6-EGFP cells (green curves) transfected with a non-EGFP
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knockdown). One day post-electroporation all samples were
cleaned of debris by OptiPrep treatment and then kept in culture
for another 4 days, with samples for Western blotting taken at days
3 and 5 post-electroporation. At low voltages (here: 120 V)
virtually no cell death ensued, but neither were any EGFP-positive
cells visible. At the high end (here: 320 V) the transfection
efficiency was about 20%, but a large number of cells did not
survive the procedure (Fig. 5, top panel – upper row). After debris
removal the increase in EGFP expression within the live cell
fraction with rising voltages was clearly visible (Fig. 5, top panel –
lower row), although this came at the expense of lower absolute
numbers of live cells (not shown). Staining for ERK2 showed that
about the same level of depletion was achieved for voltages of 200
and higher (Fig. 5, lower panel). 200 V corresponded to the setting
at which EGFP-positive cells began to appear in substantial
quantities (11.4% in the exemplary experiment shown in Fig. 5
(upper panel)). No differences in ERK2 knockdown efficiency were
observed between cells harvested at days 3 and 5 post-electropo-
ration, although it remains possible that the effect might fade faster
for lower voltage settings if still longer-term cultures were
evaluated. These experiments show that in siRNA electroporations
of MM cells milder voltage settings are permissible, and that an
‘‘imperfect’’ indicator – such as the EGFP-N3 plasmid used here –
can be used to demarcate a suitable lower limit. Such consider-
ations are important because – as with any other transfection
technique – confounding aspects of the effects of electroporation-
based methods on the cellular assays performed must always be
accounted for [31]. Of note, annexin V/PI-staining of the cultured
AMO-1 cells at day 5 post-electroporation (i.e. day 4 post-
OptiPrep purification) showed no substantial differences in
apoptosis between the different voltage settings, showing that
viable cells isolated at day 1 post-electroporation recovered well
targeting siRNA. Knockdown efficiency was essentially identical in
strength and over time between both purification approaches. One
representative experiment from a total of three is shown.
doi:10.1371/journal.pone.0097443.g003
Figure 4. Knockdown efficiency in MM cells. Knockdown of ERK2 in different MM cell lines after transfection with either a short-hairpin
expression vector (pSU-ERK2) or the ‘‘corresponding’’ target sequence synthesised as 25 bp stealth siRNA (stERK2; see Methods and [21]). At day 1
post-electroporation half of the transfected culture was subjected to the column purification method (also see Fig. 1b)–e)) (resp. cell sorting for AMO-
1 cells) and the other half to debris removal only (also see Fig. 1f)). Cells were harvested for Western blotting at the times indicated. Empty pSUPER
vector (pSU) transfected cells served as controls. The blots show that the ERK2 knockdown efficiency for stealth siRNA is virtually identical between
cells that only underwent debris removal and those that were subjected to the column purification procedure. ERK2 knockdown using the short-
hairpin expression vector was less efficient in debris-removal-only samples compared with their cognate column purification complements (see JJN-3,
L-363). Representative experiments (JJN-3: n = 3; L-363: n = 2, AMO-1: n = 2) are shown. Anti-ERK1/2 antibody: CST.
doi:10.1371/journal.pone.0097443.g004
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even for the highest voltages applied (Fig. 5, middle panel – lower
row).
General Applicability of Electroporation Procedures for
MM Cells
Based on EGFP expression we distinguish the MM cell lines
available in our laboratory as either easy to electroporate (i.e.
generally yielding transfection rates .10%, e.g. AMO-1, INA-6,
Figure 5. Voltage dependence of electroporation and knockdown efficiency in AMO-1 cells. Transfection of AMO-1 cells across a range of
voltages using an expression vector for EGFP (pEGFP-N3) and a stealth siRNA against ERK2 (stERK2) in the electroporation mixture. Top panel:
increases of the fractions of EGFP-expressing as well as of dead cells with higher voltages (top row). Cells taken in culture after OptiPrep-mediated
debris removal reflect only the increase in transfection efficiency for the EGFP expression plasmid (bottom row). Middle panel: purified AMO-1 cells
(those shown in the upper panel, bottom row) after culture for another 4 days. Top row: EGFP expression. Bottom row: annexin V-PromoFluor 647/PI
staining. Even for the highest voltage used (320 V) the purified live cell fraction did not fare worse in subsequent culture than cells electroporated
under milder conditions. Bottom panel: Western analysis of ERK2 knockdown at days 3 and 5 post-electroporation from the same cultures from which
the FACS panels were derived. Efficient siRNA-mediated ERK2 knockdown was achieved at voltages significantly lower than required for the best
levels of plasmid electroporation. However, a lower limit for successful knockdown was reached between the settings for 160 and 200 V. Shown is a
representative experiment of two complete sets (Western blotting included). Anti-ERK1/2 antibody: CST.
doi:10.1371/journal.pone.0097443.g005
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JJN-3, L-363, MM.1S, MOLP-8, U-266), or as hard to
electroporate (NCI-H929, OPM-2, RPMI-8226; Table 1). We
therefore tested if siRNA-mediated ERK2 knockdown was also
productive in the latter cell lines, which we consider unsuitable for
our plasmid-based knockdown protocols. MM cells were electro-
porated with either the ERK2 stealth siRNA or an unspecific
control stealth siRNA as well as with the pEGFP-N3 marker
plasmid, and dead cells were removed via OptiPrep gradient at
day one post-electroporation (Fig. 6, left panel). ERK2 knockdown
and reduction of intrinsic phospho-ERK2 levels were subsequently
determined by Western blotting. The extent of ERK2 knockdown
in OPM-2 and RPMI-8226 cells was roughly on a par with levels
achieved in AMO-1 and JJN-3 cells (Fig. 6, right panel), showing
that MM cell lines that only display low EGFP expression plasmid
penetrance can still successfully be used in siRNA electroporation
experiments. Similar to the dependence on voltage discussed
above, a modicum of EGFP expression suffices to indicate
conditions suitable for successful electroporation with siRNAs.
General Considerations on the Use of Electroporation-
based Knockdown Protocols with MM Cell Lines
RNA interference experiments are powerful means to conduct
loss-of-function analyses, be they in order to complement
experiments with pharmacological inhibitors or to analyse targets
for which suitable inhibitors have not yet been developed. Because
MM cell lines generally grow in suspension or at best semi-
adherently, they belong among the harder-to-manipulate cell types
by transient transfection methodologies. Even though a number of
papers either deal with this issue or report MM cell transfection in
their methods chapter [14,15,16,17,18,19,20], a robustly workable
and widely-used protocol has not yet emerged. Our analyses of
MM cell electroporability with siRNAs were therefore not only
intended to address the purely functional aspects, but also to judge
whether such a protocol could i) easily be performed and
replicated by other researchers in their laboratories, ii) prove
cost-effective, and iii) could be applied to generate sufficient
numbers of transfected cells to conduct experiments that require
substantial amounts of material, such as, for example, nuclear
preparations (i.e. cell numbers in the range of several millions
rather than hundreds of thousands). Regarding ease-of-perfor-
mance electroporation certainly fits the bill, since all that is
required is an electroporation device in addition to standard cell
culture laboratory equipment. A very basic instrument, capable of
providing an exponential decay-type current is sufficient. It has
been described for other cell lines that electroporation protocols
employing more than one electric pulse [32] or continuous square
pulsing at two different field strengths [30] can result in superior
rates of transfection, as determined by EGFP expression. Although
we have occasionally tested square pulse-type current deliveries we
have not found this to consistently achieve (much) better rates in
EGFP-expressing MM cells than a single standard exponential
decay-type pulse. Regarding electroporation of siRNAs such
differences become moot anyway, as we have shown here that
the whole surviving MM cell fraction is successfully being
transfected. In terms of cost effectiveness, the main expense is
the need to buy siRNAs. Because different sequences and different
targets may yield different knockdown results (depending, amongst
other factors, on protein expression levels and the rate of protein
turnover) we would recommend to titrate the effects of a new
siRNA employed in electroporation. Based on hands-on experi-
ence with about 15 different siRNAs and targets a concentration of
between 1–3 mM in the electroporation mix is usually required.
80 nM of a custom-built siRNA will currently (2014) cost about
450 J and provides enough reagent for 50 electroporations at
3 mM concentration and 500 ml of cell suspension (the standard
volume we use in 4 mm electroporation cuvettes). Using 2 mm
cuvettes it is sufficient for 125 electroporations a` 3 mM/200 ml.
These numbers are certainly no worse than, for example, expenses
incurred for many antibodies used in a world-wide standard
procedure such as Western blotting. Finally, an especially
appealing aspect of the protocol is the ease with which it can be
scaled up. Densities of up to 56107 MM cells/ml are entirely
permissible, which for an electroporation in 200 ml volume
translates into 16107 cells of which about 3–56106 should be
recoverable alive after OptiPrep cleaning at day 1 post-electropo-
ration. This is sufficient for multiple parallel measurements, such
Figure 6. Electroporation and knockdown efficiencies in ‘‘easy-to-transfect’’ vs. ‘‘hard-to-transfect’’ MM cell lines. Left-hand panel:
MM cell lines were electroporated with an expression vector for EGFP (pEGFP-N3; 10 mg/ml) and stealth siRNAs against either ERK2 (stERK2; 3 mM) or
against no specific target (control; 3 mM). The FACS-measurements represent the cell cultures at day 1 post-electroporation after debris removal with
OptiPrep. Right-hand panel: Knockdown of ERK2 and intrinsic levels of phospho-ERK2 (cells from the cultures represented on the left were harvested
at day 3 post-electroporation for Western blotting). Good knockdown of ERK2 and lowered levels of phospho-ERK2 were found for all four MM cell
lines tested. Shown is a representative experiment of two complete sets (Western blotting included). Anti-ERK1/2 antibody: Santa Cruz
Biotechnology.
doi:10.1371/journal.pone.0097443.g006
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as cell death determinations, proliferation assays, Western analyses
etc. at various time-points, and obviously more electroporations
can effortlessly be performed if still higher cell numbers are
needed. Taken together, we believe that the siRNA electropora-
tion procedure detailed here can confidently be employed in any
laboratory devoted to MM cell research.
Supporting Information
Figure S1 Electroporation of RPMI-8226 cells with a 6-
FAM-labelled siRNA oligonucleotide. Top: Fluorescence of
RPMI-8226 cells electroporated with the siERK2-6-FAM oligo-
nucleotide (green curve) in relation to mock transfected cells (blue
curve) at different time points post-electroporation (p.e.). Bottom:
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